Clinical trial · Interventional
Endovascular Denervation in Patients With Cancer Pain
NCT03431922CI-TRIAL-00031659unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endovascular arterial denervation (ED) is a minimally invasive technique which could reduce the occurrence of injury of visceral tissue or organs. As the principle of renal denervation (RDN), Radiofrequency energy delivered by a multi-electrode catheter to the celiac plexus over the anterolateral surface of the superior mesenteric artery (SMA) and the celiac axis. Damaged or partially damaged celiac plexus can achieve the effect of pain relief.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endovascular denervation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- endovascular denervation
- description
- endovascular denervation
- interventionNames
- Device: endovascular denervation
Primary outcomes (1)
- measure
- Pain relief
- timeFrame
- from baseline to 1 months after procedure
- description
- Changes of the visual analogue scores (VAS) scores
Secondary outcomes (3)
- measure
- Pain relief
- timeFrame
- from baseline to 3 months after procedure
- description
- Changes of the visual analogue scores (VAS) scores
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 25 to 75 years * severe cancer pain with the visual analogue scores of no less than 7 Exclusion Criteria: * pregnant or intent to become pregnant within 1 year * postural hypotension * uncorrected coagulation dysfunction * aortic aneurysm or dissection * type 1 diabetes mellitus (T1DM) * acute or severe systemic infection * history of cerebral apoplexy or transient ischemic attack (TIA) in the past two weeks * history of acute coronary syndrome in the past two weeks * participants who are not suitable to be enrolled into the study assessed by the researchers
References
Publications (3)
- BACKGROUNDde Oliveira R, dos Reis MP, Prado WA. The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain. Pain. 2004 Jul;110(1-2):400-8. doi: 10.1016/j.pain.2004.04.023. PMID 15275792
- BACKGROUNDWong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Mantilla CB, Warner DO. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1092-9. doi: 10.1001/jama.291.9.1092. PMID 14996778
- BACKGROUNDCleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994 Mar 3;330(9):592-6. doi: 10.1056/NEJM199403033300902. PMID 7508092